

## Tentative Daily Programme

Theme: Expanding Hepatitis C therapy beyond individual cure to elimination

*Day 1, Friday 3<sup>rd</sup> August 2018*

<b>Opening Ceremony</b>	
<b>0815 - 0900 (45 mins)</b>	<b>Welcome Address Keynote Address</b>
<b>Plenary 1</b>	
<b>0900 - 0930 (30 mins)</b>	<b>Hepatitis C epidemiology: heralding a public health burden</b>
<b>Plenary 2</b>	
<b>0930 - 1000 (30 mins)</b>	<b>The HCV treatment landscape in 2018</b>
<b>1000 - 1030 (30 mins)</b>	<b>Coffee break/Exhibition booths/Poster viewing</b>
<b>Symposium 1 : Approach to challenging HCV cases</b>	
<b>1030 - 1140 (70 mins)</b>	<ul style="list-style-type: none"><li>• <i>Identifying the cirrhotics and their unique management (20 mins)</i></li><li>• <i>Co-infection: HCV in people living with HIV/HBV (20 mins)</i></li><li>• <i>ESRD and other extrahepatic manifestations (20 mins)</i></li><li>• <i>Q&amp;A (10 mins)</i></li></ul>
<b>1140-1240 (60 mins)</b>	<b>Lunch Symposium</b>
<b>1300-1430 (90 mins)</b>	<b>Poster Rounds</b>
<b>Symposium 2 : The Road to Hepatitis C elimination</b>	
<b>1430-1520 (50 mins)</b>	<ul style="list-style-type: none"><li>• <i>In Asia – Our successes, the gaps and challenges ahead (20 mins)</i></li><li>• <i>Screening strategies – the pros and cons of targeted vs birth cohorts (20 mins)</i></li><li>• <i>Q&amp;A (10 mins)</i></li></ul>
<b>Symposium 3: Asia Pacific HCV experience –sharing pearls of wisdom</b>	
<b>1515 - 1630 (75 mins)</b>	<ul style="list-style-type: none"><li>• <i>Scaling up treatment: barriers despite affordable DAA (15 mins)</i></li><li>• <i>Innovations to maximize diagnosis and treatment opportunities (15 mins)</i></li><li>• <i>India: Treatment response to generic DAAs (15 mins)</i></li><li>• <i>HCV treatment under national health care financing (15 mins)</i></li><li>• <i>Round table discussion/questions (15 mins)</i></li></ul>
<b>1630 - 1730 (60 mins)</b>	<b>Tea Symposium</b>
<b>1930</b>	<b>Faculty Dinner (by invitation)</b>

## *Day 2, Saturday 4<sup>th</sup> August 2018*

Plenary 3	
0830-0900 (30 mins)	Is B like C-will it be curable?
Symposium 4: Emerging obstacles in HCV management/eliminations	
0900 – 09550 (55 mins)	<ul style="list-style-type: none"> <li>• Management of DAA failures in Asia (15 mins)</li> <li>• Role of DAA in decompensated cirrhotic – Is there a point of no return? (15 mins)</li> <li>• Is elimination of HCV an attainable priority from an economic perspective? (15 mins)</li> <li>• Q&amp;A (10 mins)</li> </ul>
0955 - 1025 (30 mins)	Coffee break/Poster rounds
Symposium 5 : Hepatitis C and other concurrent disease	
1025 – 1120 (55 mins)	<ul style="list-style-type: none"> <li>• HCC and HCV therapy- is there increased risk? (15 mins)</li> <li>• GT3 HCV with concomitant fatty liver-will steatosis go away? (15 mins)</li> <li>• HCV patients also needing immunosuppressive therapy-what is important? (15 mins)</li> <li>• Q&amp;A (10 mins)</li> </ul>
Case Discussion	
1120 – 1220 (60 mins)	Case discussions
1220 – 1320 (60 mins)	Lunch Symposium
Symposium 6 : Impactful advocacy Panelists :	
1400 – 1520 (80 mins)	<ul style="list-style-type: none"> <li>• Treatment as prevention-engaging the marginalized (15 mins)</li> <li>• Breaking the stigma and barriers in society (15 mins)</li> <li>• Community based program – achievements rising and challenges (15 mins)</li> <li>• The voice of hepatitis-my experience and my actions (10 mins x 2 persons)</li> <li>• Q&amp;A (15 mins)</li> </ul>
From 1520	NGO Workshop/Tea will be served

## *Day 3, Sunday 5<sup>th</sup> August 2018*

### *HCV Management Session*

Introduction	
0800 - 0820	Hepatitis C-the burden, management cascade and goals
Screening and baseline assessments	
0820 - 0925	<ul style="list-style-type: none"> <li>• Scaling up screening for hepatitis C - how and what I do?</li> <li>• Baseline pre-treatment assessments : -             <ul style="list-style-type: none"> <li>- history, examination &amp; tests – what do I do?</li> <li>- how do I tackle drug-drug interactions and ensure adherence?</li> </ul> </li> <li>• Q&amp;A</li> </ul>

<b>Treatment initiation and monitoring</b>	
0925 - 1010	<ul style="list-style-type: none"> <li>• The treatments available in 2018 <ul style="list-style-type: none"> <li>- how do I select the right one for my patient?</li> </ul> </li> <li>• On treatment monitoring and optimizing outcome <ul style="list-style-type: none"> <li>- best and innovative approach</li> </ul> </li> <li>• Q&amp;A</li> </ul>
1010	Coffee break
<b>Post treatment management</b>	
1040-1125	<ul style="list-style-type: none"> <li>• After SVR- to discharge or not to discharge?</li> <li>• Failed SVR to DAA-what is next?</li> <li>• Q&amp;A</li> </ul>
<b>Case Discussion 1</b>	
1125 - 1225	Case Discussion Panelists : TBC
1225 - 1325	Lunch Symposium
<b>Dealing with complications of liver cirrhosis</b>	
1325 - 1430	<ul style="list-style-type: none"> <li>• An update on management of ascites</li> <li>• An update on management of hepatic encephalopathy</li> <li>• An update on management of variceal bleeding</li> <li>• An update on management of small HCC</li> <li>• Q&amp;A</li> </ul>
<b>Case Discussion 2</b>	
1430-1530	1 long case/2 short cases Panelists : TBC
1530	Closing Remarks